Jiayi Wu

Fudan University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.0kcitations119works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(72), HER2/EGFR in Cancer Research(44), Advanced Breast Cancer Therapies(27), Breast Lesions and Carcinomas(18), Cancer Treatment and Pharmacology(18)

Publications118 total

Spatiotemporal Continuity and Spatially Heterogeneous Drivers in the Historical Evolution of County-Scale Carbon Emissions from Territorial Function Utilisation in China: Evidence from Qionglai City
Land·2025· 1 citedOpen Access
Accelerometer-measured physical activity, sedentary behavior, and incident neuropsychiatric diseases: a large prospective cohort study of 73411 participants
Molecular Psychiatry·2025· 2 cited
Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple‐Negative Breast Cancer
Journal of Extracellular Vesicles·2025Open Access
Abstract P4-10-12: Abemaciclib monotherapy after disease progression on prior CDK4/6 inhibitors in patients with metastatic hormone-receptor positive breast cancer
Clinical Cancer Research·2025
Accelerometer-Measured Physical Activity, Sedentary Behavior, and Incident Neuropsychiatric Diseases: A Large Prospective Cohort Study of 73,411 Participants (S1.003)
Neurology·2025
The value of a metabolic and immune-related gene signature and adjuvant therapeutic response in pancreatic cancer
Frontiers in Genetics·2025· 3 citedOpen Access
Short-term exposure of enrofloxacin inhibits synthesis of central estradiol through secretoneurin a/aromatase B (cyp19a1b) pathway in crucian carp
Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology·2024· 2 cited
Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.
Journal of Clinical Oncology·2024
Safety analysis of immediate breast reconstruction with a deep inferior epigastric perforator (DIEP) flap in the post-COVID-19 era: a comparison between pre- and post-pandemic cohorts
Gland Surgery·2023· 1 citedOpen Access
Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
Cell Death and Disease·2023· 59 citedOpen Access
Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
Gland Surgery·2023· 5 citedOpen Access
Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
Frontiers in Immunology·2023· 98 citedOpen Access
A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer
Frontiers in Pharmacology·2023· 8 citedOpen Access
Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression
BMC Cancer·2023· 18 citedOpen Access
Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
2023· 1 citedOpen Access
Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
Frontiers in Oncology·2023· 2 citedOpen Access
Nodal Underestimation Rate in Early-Stage ER /HER2- Breast Cancer Patients with Limited Positive Sentinel Lymph Nodes in the Era of Precise Medication: A Real-World Multicenter Analysis from 40 Institutions in China
SSRN Electronic Journal·2023Open Access
Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients
European journal of medical research·2022· 4 citedOpen Access
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
Breast Cancer Research and Treatment·2022· 14 cited
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
Research Square (Research Square)·2022· 1 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Kunwei Shen(49), Ou Huang(38), Weiguo Chen(36), Xiaosong Chen(35), Li Zhu(33), Jianrong He(28), Yafen Li(26), Xiaochun Fei(15), Jin Hong(10), Siji Zhu(10), Yu Zong(8), Cai‐Jin Lin(8), Shuning Ding(8), Yafen Li(8), Weiqi Gao(7), Yiwei Tong(6), Jiahui Huang(6), Deyue Liu(5), Lisa Andriani(5), Wei Wang(4)